LUND, Sweden, Dec. 29, 2020 /PRNewswire/ -- Alligator
Bioscience (Nasdaq Stockholm: ATORX) today announced that
the company has appointed Dr Christina
Reimer as Chief Medical Officer. She most recently comes
from a position as Senior Medical Director at Ferring
Pharmaceuticals in Copenhagen.
Dr Reimer will replace Dr Charlotte
Russel and be overall medically responsible for Alligator's
drug development candidates, with an emphasis on bringing
mitazalimab and ATOR-1017 into Phase II efficacy studies. She
will report to Head of R&D, EVP Malin Carlsson, and be part of
the management team.
"I am very pleased with the successful recruitment of
Christina Reimer to Alligator. Her
international experience in leading clinical development and in
building development organizations will significantly strengthen
our clinical capacity. This is crucial in the phase we are in now,
with two products on the way to Phase II and another product in
clinical Phase I. We look forward to welcoming Christina to
Lund and to our management team",
said Per Norlén, CEO of Alligator Bioscience.
Christina Reimer is a medical
doctor with specialist qualifications and a PhD in
gastroenterology. She also has considerable experience from leading
clinical programs within the industry. Christina Reimer will assume the role of Chief
Medical Officer (CMO) at Alligator on February 1, 2021.
"Alligator's solid science-based approach to discover new cancer
treatments and the fact that they have several assets in clinical
development is what makes this opportunity unique. I hope to be
able to apply my many years of clinical experience with cancer
patients and my clinical drug development skills to progress
Alligator's assets through the next important steps of development.
I look very much forward to become part of the team at Alligator",
said Christina Reimer.
For further information, please contact:
Cecilia Hofvander, Director
Investor Relations & Communications
Phone +46 46 540 82 06
E-mail: cecilia.hofvander@alligatorbioscience.com
The information was submitted for publication, through the
agency of the contact person set out above, at 9:00 a.m.
CET on December 29,
2020.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology
company developing tumor-directed immuno-oncology antibody drugs.
Alligator's pipeline includes the two key assets ATOR-1017 and
mitazalimab. Furthermore, there are two partnered assets:
ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and
AC101 in clinical development by Shanghai Henlius Biotech Inc. In
addition, the company has developed a novel concept for more
patient-specific immunotherapy: Neo-X-Prime. Alligator's shares are
listed on Nasdaq Stockholm (ATORX). The Company is headquartered in
Lund, Sweden. For more
information, please visit www.alligatorbioscience.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-recruits-new-chief-medical-officer,c3262472
The following files are available for download:
https://mb.cision.com/Main/12681/3262472/1354774.pdf
|
Alligator Bioscience
recruits new Chief Medical Officer
|
View original
content:http://www.prnewswire.com/news-releases/alligator-bioscience-recruits-new-chief-medical-officer-301198908.html
SOURCE Alligator Bioscience